Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15

Oppenheimer analyst Les Sulewski has initiated coverage on Cormedix (NASDAQ: CRMD) with an Outperform rating. The firm has set a price target of $15 for the company's stock.